• Adoption of the resolutions at the Extraordinary General Meeting held today relating to the capital increase to take place in January 2024
Bordeaux, Boston, November 16, 2023 – 7:00 p.m. CET: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), medical technology company specializing in implants intended for orthopedic surgery and in the distribution of technological medical equipment, announces that it has obtained the approval of its shareholders regarding the completion of the upcoming capital increase operation.
As announced in its press release of October 11, 2023, IMPLANET had convened its shareholders for an Extraordinary General Meeting today in order in particular to submit to their vote the resolutions aimed at authorizing the implementation of a capital increase with maintenance of preferential rights subscription of an amount between €5.5 million and €6.4 million (excluding possible exercise of an extension option of 15% maximum) to take place in January 2024.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]